Kong Yun-hua, Zhang Liang, Yang Zheng-yi, Han Cong, Hu Li-hong, Jiang Hua-liang, Shen Xu
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Acta Pharmacol Sin. 2008 Jul;29(7):870-6. doi: 10.1111/j.1745-7254.2008.00808.x.
To investigate the inhibition features of the natural product juglone (5- hydroxy-1,4-naphthoquinone) against the three key enzymes from Helicobacter pylori (cystathionine gamma-synthase [HpCGS], malonyl-CoA:acyl carrier protein transacylase [HpFabD], and beta-hydroxyacyl-ACP dehydratase [HpFabZ]).
An enzyme inhibition assay against HpCGS was carried out by using a continuous coupled spectrophotometric assay approach. The inhibition assay of HpFabD was performed based on the alpha-ketoglutarate dehydrogenase-coupled system, while the inhibition assay for HpFabZ was monitored by detecting the decrease in absorbance at 260 nm with crotonoyl-CoA conversion to beta -hydroxybutyryl-CoA. The juglone/FabZ complex crystal was obtained by soaking juglone into the HpFabZ crystal, and the X-ray crystal structure of the complex was analyzed by molecular replacement approach.
Juglone was shown to potently inhibit HpCGS, HpFabD, and HpFabZ with the half maximal inhibitory concentration IC50 values of 7.0 +/-0.7, 20 +/-1, and 30 +/-4 micromol/L, respectively. An inhibition-type study indicated that juglone was a non-competitive inhibitor of HpCGS against O-succinyl- L-homoserine (Ki=alphaKi=24 micromol/L), an uncompetitive inhibitor of HpFabD against malonyl-CoA (alphaKi=7.4 micromol/L), and a competitive inhibitor of HpFabZ against crotonoyl-CoA (Ki=6.8 micromol/L). Moreover, the crystal structure of the HpFabZ/juglone complex further revealed the essential binding pattern of juglone against HpFabZ at the atomic level.
HpCGS, HpFabD, and HpFabZ are potential targets of juglone.
研究天然产物胡桃醌(5-羟基-1,4-萘醌)对幽门螺杆菌的三种关键酶(胱硫醚γ-合酶[HpCGS]、丙二酰辅酶A:酰基载体蛋白转酰基酶[HpFabD]和β-羟基酰基-ACP脱水酶[HpFabZ])的抑制特性。
采用连续偶联分光光度法对HpCGS进行酶抑制试验。基于α-酮戊二酸脱氢酶偶联系统进行HpFabD的抑制试验,而通过检测巴豆酰辅酶A转化为β-羟基丁酰辅酶A时260nm处吸光度的降低来监测HpFabZ的抑制试验。将胡桃醌浸泡到HpFabZ晶体中获得HpFabZ/胡桃醌复合物晶体,并通过分子置换法分析该复合物的X射线晶体结构。
胡桃醌对HpCGS、HpFabD和HpFabZ具有显著抑制作用,半数最大抑制浓度IC50值分别为7.0±0.7、20±1和30±4μmol/L。抑制类型研究表明,胡桃醌是HpCGS对O-琥珀酰-L-高丝氨酸的非竞争性抑制剂(Ki =αKi = 24μmol/L),是HpFabD对丙二酰辅酶A的反竞争性抑制剂(αKi = 7.4μmol/L),是HpFabZ对巴豆酰辅酶A的竞争性抑制剂(Ki = 6.8μmol/L)。此外,HpFabZ/胡桃醌复合物的晶体结构进一步在原子水平上揭示了胡桃醌与HpFabZ的关键结合模式。
HpCGS、HpFabD和HpFabZ是胡桃醌的潜在作用靶点。